Five-year efficacy and safety of tafasitamab in patients with relapsed or refractory DLBCL: Final results from the phase II L-MIND study Meeting Abstract
| Authors: | Düll, J.; Abrisqueta, P.; Andre, M.; Augustin, M.; Gaidano, G.; Barca, E. G.; Jurczak, W.; Kalakonda, N.; Liberati, A. M.; Maddocks, K. J.; Menne, T.; Nagy, Z.; Tournilhac, O.; Bakuli, A.; Amin, A.; Gurbanov, K.; Salles, G. |
| Abstract Title: | Five-year efficacy and safety of tafasitamab in patients with relapsed or refractory DLBCL: Final results from the phase II L-MIND study |
| Meeting Title: | Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie (2023) |
| Journal Title: | Oncology Research and Treatment |
| Volume: | 46 |
| Issue: | Suppl. 5 |
| Meeting Dates: | 2023 Oct 13-16 |
| Meeting Location: | Hamburg, Germany |
| ISSN: | 2296-5270 |
| Publisher: | S. Karger AG |
| Date Published: | 2023-10-01 |
| Start Page: | 214 |
| Language: | English |
| ACCESSION: | WOS:001091456900461 |
| PROVIDER: | wos |
| PUBMED: | 37788643 |
| DOI: | 10.1159/000533576 |
| Notes: | Meeting Abstract: P412 -- Source: Wos |
